LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo

Microvascular Research

Volumn 82, Issue 2, 2011, Pages 122-130

  Gao, Jian Jun ^a   Xue, Xia ^a   Gao, Zu Hua ^b   Cui, Shu Xiang ^c   Cheng, Yan Na ^a   Xu, Wen Fang ^a   Tang, Wei ^d   Qu, Xian Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b CALGARY LABORATORY SERVICES   (Canada)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BESTATIN; BESTATIN DERIVATIVE; CD34 ANTIGEN; LYP; MICROSOMAL AMINOPEPTIDASE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CANCER INHIBITION; CAPILLARY DENSITY; CELL INVASION; CELL LEVEL; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD13; CELL MEMBRANE; ENDOTHELIUM, VASCULAR; ESTERS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LEUCINE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSFORMING GROWTH FACTOR ALPHA; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 79960915343     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.05.008     Document Type: Article

References (34)

1. Alonso-Camino V., Santos-Valle P., Ispizua M.C., Sanz L., Alvarez-Vallina L. Engineered human tumor xenografts with functional human vascular networks. Microvasc. Res. 2011, 81:18-25.
2. Aozuka Y., Koizumi K., Saitoh Y., Ueda Y., Sakurai H., Saiki I. Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice. Cancer Lett. 2004, 216:35-42.
3. Bank U., Bohr U.R., Reinhold D., Lendeckel U., Ansorge S., Malfertheiner P., Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci. 2008, 13:3699-3713.
4. Bhagwat S.V., Lahdenranta J., Giordano R., Arap W., Pasqualini R., Shapiro L.H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001, 97:652-659.
5. Chang S.H., Kanasaki K., Gocheva V., Blum G., Harper J., Moses M.A., Shih S.C., Nagy J.A., Joyce J., Bogyo M., Kalluri R., Dvorak H.F. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009, 69:4537-4544.
6. Chen M.H., Cui S.X., Cheng Y.N., Sun L.R., Li Q.B., Xu W.F., Ward S.G., Tang W., Qu X.J. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity. Anticancer Drugs 2008, 19:957-965.
7. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A.R., Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001, 7:1459-1465.
8. Cui S.X., Qu X.J., Gao Z.H., Zhang Y.S., Zhang X.F., Zhao C.R., Xu W.F., Li Q.B., Han J.X. Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells. Cancer Lett. 2010, 292:153-162.
9. Dias P.F., Siqueira J.M., Maraschin M., Ferreira A.G., Gagliardi A.R., Ribeiro-do-Valle R.M. A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis. Microvasc. Res. 2008, 75:34-44.
10. Fukasawa K., Fujii H., Saitoh Y., Koizumi K., Aozuka Y., Sekine K., Yamada M., Saiki I., Nishikawa K. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett. 2006, 243:135-143.
11. Gao F.J., Cui S.X., Chen M.H., Cheng Y.N., Sun L.R., Ward S.G., Kokudo N., Tang W., Qu X.J. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci. 2008, 83:815-820.
12. Gao J.J., Gao Z.H., Zhao C.R., Yuan Y., Cui S.X., Zhang X.F., Cheng Y.N., Xu W.F., Tang W., Qu X.J. LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin. Invest. New Drugs 2010, [Epub ahead of print].
13. Inagaki Y., Tang W., Zhang L., Du G., Xu W., Kokudo N. Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. BioSci. Trends 2010, 4:56-60.
14. Kehlen A., Lendeckel U., Dralle H., Langner J., Hoang-Vu C. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 2003, 63:8500-8506.
15. Lee A.H., Dublin E.A., Bobrow L.G., Poulsom R. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J. Pathol. 1998, 185:394-401.
16. Luan Y.P., Wang X.J., Zhu H.W., Qu X.J., Fang H., Xu W.F. The synthesis and activity evaluation of a bestatin derivative (LYP) as an aminopeptidase N inhibitor. Lett. Drug Des. Discov. 2009, 6:420-423.
17. Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol. Med. 2008, 14:361-371.
18. Mishima Y., Terui Y., Sugimura N., Matsumoto-Mishima Y., Rokudai A., Kuniyoshi R., Hatake K. Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells. Cancer Sci. 2007, 98:364-372.
19. Mou J., Fang H., Jing F., Wang Q., Liu Y., Zhu H., Shang L., Wang X., Xu W. Design, synthesis and primary activity evaluation of l-arginine derivatives as amino-peptidase N/CD13 inhibitors. Bioorg. Med. Chem. 2009, 17:4666-4673.
20. Nishi H., Inoue Y., Kageshita T., Takata M., Ihn H. The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. BioSci. Trends 2010, 4:86-89.
21. Okutucu B., Dincer A., Habib O., Zihnioglu F. Comparison of five methods for determination of total plasma protein concentration. J. Biochem. Biophys. Methods 2007, 70:709-711.
22. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60:722-727.
23. Perez I., Varona A., Blanco L., Gil J., Santaolalla F., Zabala A., Ibarguen A.M., Irazusta J., Larrinaga G. Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck 2009, 31:1335-1340.
24. Petrovic N., Bhagwat S.V., Ratzan W.J., Ostrowski M.C., Shapiro L.H. CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J. Biol. Chem. 2003, 278:49358-49368.
25. Qi F.H., Li A.Y., Lv H., Zhao L., Li J.J., Gao B., Tang W. Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. Drug Discov. Ther. 2008, 2:339-343.
26. Qu X.J., Yang J.L., Russell P.J., Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J. Urol. 2004, 172:733-738.
27. Rangel R., Sun Y., Guzman-Rojas L., Ozawa M.G., Sun J., Giordano R.J., Van Pelt C.S., Tinkey P.T., Behringer R.R., Sidman R.L., Arap W., Pasqualini R. Impaired angiogenesis in aminopeptidase N-null mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4588-4593.
28. Reinhold D., Bank U., Tager M., Ansorge S., Wrenger S., Thielitz A., Lendeckel U., Faust J., Neubert K., Brocke S. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci. 2008, 13:2356-2363.
29. Riemann D., Kehlen A., Langner J. CD13-not just a marker in leukemia typing. Immunol. Today 1999, 20:83-88.
30. Terauchi M., Kajiyama H., Shibata K., Ino K., Nawa A., Mizutani S., Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. B.M.C. Cancer 2007, 7:140.
31. Truong N.P., Jia Z., Burges M., McMillan N.A., Monteiro M.J. Self-catalyzed degradation of linear cationic poly(2-dimethylaminoethyl acrylate) in water. Biomacromolecules 2011, [Epub ahead of print].
32. Wang S.B., Cheng Y.N., Cui S.X., Zhong J.L., Ward S.G., Sun L.R., Chen M.H., Kokudo N., Tang W., Qu X.J. Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin. Exp. Metastasis 2009, 26:469-477.
33. Wulfaenger J., Niedling S., Riemann D., Seliger B. Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Mol. Membr. Biol. 2008, 25:72-82.
34. Zhang X., Zhong J.L., Liu W., Gao Z., Xue X., Yue P., Wang L., Zhao C., Xu W., Qu X. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemother. Pharmacol. 2010, 66:11-19.